Anti–IL-10 Autoantibodies Define a New Subgroup of IBD: NEJM | June 2026

• This landmark study identifies neutralizing autoantibodies against interleukin-10 (IL-10) as a previously underrecognized mechanism driving inflammatory bowel disease.
• IL-10 is a critical anti-inflammatory cytokine that maintains intestinal immune tolerance. Genetic defects in the IL-10 pathway are already known to cause severe early-onset IBD.
• The investigators found neutralizing anti–IL-10 autoantibodies in 3.5% of patients with IBD, but in none of the healthy controls, suggesting a disease-specific phenomenon.
• Anti–IL-10 autoantibodies were detected across Crohn’s disease, ulcerative colitis, and IBD-unclassified populations.
• Functional studies confirmed that these antibodies are not merely biomarkers; they actively block IL-10 signaling and create a pro-inflammatory immune environment.
• Patients with anti–IL-10 antibodies demonstrated exaggerated production of key inflammatory cytokines, including: * IL-23 * IL-1β * TNF * IL-6
• The most striking finding was the exceptionally strong association with HLA-DRB1*01:03, already recognized as the strongest genetic risk factor for ulcerative colitis.
• More than 80% of anti–IL-10-positive patients carried HLA-DRB1*01:03, providing a mechanistic explanation for one of the strongest known HLA associations in IBD.
• The association was remarkably strong, with odds ratios ranging from approximately 25 to 50 across independent cohorts.
• Anti–IL-10 autoantibodies persisted over many years in most affected patients, suggesting a stable and durable immunological phenotype.
• The study introduces the concept that some patients with IBD may have an acquired “phenocopy” of genetic IL-10 signaling defects.
• This finding expands the role of B-cell–mediated autoimmunity in IBD pathogenesis, an area previously overshadowed by T-cell and innate immune mechanisms.
• The discovery opens the possibility of a new precision-medicine subgroup of IBD defined by immune dysfunction rather than conventional clinical phenotype.
• Potential future therapeutic approaches could include: * B-cell depletion (anti-CD20, anti-CD19) * Plasma cell targeting (anti-CD38) * Fc receptor blockade * Plasma exchange * Future antigen-specific immune therapies
• Screening for anti–IL-10 antibodies may eventually become clinically relevant in patients with severe, refractory, extensive, or atypical IBD.
• Further studies are needed to determine whether anti–IL-10 positivity predicts disease severity, colectomy risk, biologic response, or extraintestinal manifestations.

Bottom line: Neutralizing anti–IL-10 autoantibodies are present in approximately 1 in 30 patients with IBD and are strongly linked to HLA-DRB1*01:03. This discovery identifies a biologically distinct autoimmune subtype of IBD and provides a potential mechanistic explanation for one of the strongest genetic risk factors in ulcerative colitis.